US MFN/Tariff Deadline July 31 – Onshoring Negotiations Intensify
Key Questions
What is the July 31 deadline for in the pharmaceutical sector?
The July 31 deadline concerns pharma tariffs and MFN onshoring requirements. Industry has committed $500B in investments, though legal experts stress the need for data-backed proposals and multi-year timelines.
How is the White House using voluntary deals in tariff negotiations?
The White House is leveraging voluntary deals like Trump Rx savings to bypass international reference pricing. This approach may determine the future of the GLOBE/GUARD demonstration models if most manufacturers participate.
What related international pricing developments are occurring alongside US tariff talks?
Discussions include the UK-US pharmaceuticals deal and AstraZeneca and Daiichi Sankyo nearing a UK pricing agreement for a breast cancer drug. These reflect broader efforts to manage pricing and onshoring pressures.
The July 31 deadline for pharma tariffs and MFN onshoring is imminent. Industry has committed $500B in investment, but legal experts emphasize data-backed proposals and multi-year timelines. The White House is leveraging voluntary deals (Trump Rx savings) to bypass international reference pricing. The fate of GLOBE/GUARD demonstration models remains uncertain; if most manufacturers sign voluntary deals, models may be abandoned. This is the top priority for market access and policy professionals.